211 related articles for article (PubMed ID: 36114912)
1. Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents.
Bagul C; Rao GK; Veena I; Kulkarni R; Tamboli JR; Akunuri R; Shaik SP; Pal-Bhadra M; Kamal A
Mol Divers; 2023 Jun; 27(3):1185-1202. PubMed ID: 36114912
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
4. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
5. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
8. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
9. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel pyrimidine-benzimidazol hybrids as potential anticancer agents.
Shao KP; Zhang XY; Chen PJ; Xue DQ; He P; Ma LY; Zheng JX; Zhang QR; Liu HM
Bioorg Med Chem Lett; 2014 Aug; 24(16):3877-81. PubMed ID: 25001482
[TBL] [Abstract][Full Text] [Related]
11. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E
Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and antitumor evaluation of novel pyrazolo[3,4-
Salem IM; Mostafa SM; Salama I; El-Sabbagh OI; Hegazy WAH; Ibrahim TS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):203-215. PubMed ID: 36382444
[TBL] [Abstract][Full Text] [Related]
13. Identification of a promising hit from a new series of pyrazolo[1,5-a]pyrimidine based compounds as a potential anticancer agent with potent CDK1 inhibitory and pro-apoptotic properties through a multistep in vitro assessment.
Elgiushy HR; Mohamed SH; Taha H; Sawaf H; Hassan Z; Abou-Taleb NA; El-Labbad EM; Hassan AS; Abouzid KAM; Hammad SF
Bioorg Chem; 2022 Mar; 120():105646. PubMed ID: 35134645
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
15. Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFR
Reda N; Mohamed KO; Abdou K; Helwa AA; Elshewy A
Bioorg Chem; 2024 Apr; 145():107185. PubMed ID: 38350273
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activities of Tetrasubstituted Imidazole-Pyrimidine-Sulfonamide Hybrids as Inhibitors of EGFR Mutants.
Alghamdi EM; Alamshany ZM; El Hamd MA; Taher ES; Farrag El-Behairy M; Norcott PL; Marzouk AA
ChemMedChem; 2023 Apr; 18(8):e202200641. PubMed ID: 36754780
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Anticancer Screening for Repurposed Pyrazolo[3,4-d]pyrimidine Derivatives on Four Mammalian Cancer Cell Lines.
Othman EM; Bekhit AA; Anany MA; Dandekar T; Ragab HM; Wahid A
Molecules; 2021 May; 26(10):. PubMed ID: 34065773
[TBL] [Abstract][Full Text] [Related]
18. Human dihydrofolate reductase inhibition effect of 1-Phenylpyrazolo[3,4-d]pyrimidines: Synthesis, antitumor evaluation and molecular modeling study.
Salem IM; Mostafa SM; Salama I; El-Sabbagh OI; A H Hegazy W; Ibrahim TS
Bioorg Chem; 2022 Dec; 129():106207. PubMed ID: 36270170
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5-
Bagul C; Rao GK; Makani VKK; Tamboli JR; Pal-Bhadra M; Kamal A
Medchemcomm; 2017 Sep; 8(9):1810-1816. PubMed ID: 30108891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
